The ESMO Manifesto: Outlining Key Areas to Unleash the Potential of the EU Beating Cancer Plan
An evidence-based and patient-centred approach to close the care gap for a healthier Europe
An evidence-based and patient-centred approach to close the care gap for a healthier Europe
Researchers investigated the risk of T-cell malignant neoplasms and any second primary malignant neoplasms in patients receiving CAR T-cell therapy for hematologic malignancies.
The first in ASTCT’s new CAR T Webinar Series aired on June 9, 2021 with our speaker, Dr. Marcela Maus, and our moderator, Dr. Armin…
Simulation-based education can improve health care professionals’ understanding and confidence regarding the treatment of patients with CAR T-cell therapy.
Are desmoid tumors benign or malignant? How are they diagnosed and treated? And, are they associated with any genetic mutations? Sarcoma specialist Shreyaskumar Patel, M.D.,…
The third prespecified interim analysis of overall survival in the phase III KEYNOTE-564 trial has shown a significant benefit with adjuvant pembrolizumab vs placebo in…
2023 Featured Articles July 13 – Biopsy-Guided Pathological Response Assessment in Breast Cancer is Insufficient: Additional Pathology Findings of the MICRA Trial Citation: van Hemert,…
Heinz-Josef Lenz, MD, FACP, discusses the prognostic value of HER2 expression in patients with KRAS wild-type metastatic colorectal cancer.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
The ASH Ambassador program supports recruitment and retention of trainees to hematology and to the Society through effective grassroots promotion of ASH’s career development and…
Published: February 13, 2024Written by: Rob LevyWhen Youling Sun was diagnosed in Shanghai, China, with acute myeloid leukemia (AML) in 2018, he called his son,…